Rx00092 - Eculizumab


Name:
Eculizumab
Rx ID:
Rx00092
Validation Level:
Phenomic Similarity:
0.609
Reference ID:
DB01257
Primary Indications:
Paroxysmal nocturnal hemoglobinuria; hemolysis
Orphan Indications:
No annotated orphan indications.
Rare Indications:
Dermatomyositis; Idiopathic membranous glomerular nephropathy; atypical hemolytic uremic syndrome
Common Indications:
Paroxysmal nocturnal hemoglobinuria; hemolysis
Drug Interactions:
No annotated drug interactions in DrugBank.
Food Interactions:
No annotated food interactions in DrugBank.

Interactive Drug Target Network

Interactive Bipartite Drug Repurposing Graph

Rx00092
Primary Indication
Secondary Indication

Disease prevalence from Electronic Health Records

Click row to show all

Disease A Disease B A∩B A∩¬B B∩¬A Odds-Ratio P-Value Adjusted P-Value
paroxysmal nocturnal hemoglobinuria hemolysis 151 151 1971 2047.146 0 0.0
hemolysis paroxysmal nocturnal hemoglobinuria 151 1971 151 2047.146 0 0.0

Chemical, Pharmacological and Biological Annotations


ATC Code:
No ATC code annotated in DrugBank
Categories:
No categories annotated in DrugBank
Classification:
Kingdom:
Organic Compounds
Superclass:
Organic Acids
Class:
Carboxylic Acids and Derivatives
Subclass:
Amino Acids, Peptides, and Analogues
Indication:
For the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis.
Pharmacodynamics:
Eculizumab is a monoclonal antibody directed against the complement protein C5. This antibody blocks the cleavage of C5 and halts the process of complement-mediated cell destruction. Eculizumab is a product of Alexion Pharmaceuticals and ha...
Click to show more...
Description:
Soliris is a formulation of eculizumab which is a recombinant humanized monoclonal IgG2/4;κ antibody produced by murine myeloma cell culture and purified by standard bioprocess technology. Eculizumab contains human constant regions fr...
Click to show more...
Mechanism:
A genetic mutation in PNH patients leads to the generation of populations of abnormal RBCs (known as PNH cells) that are deficient in terminal complement inhibitors (CD-59), rendering PNH RBCs sensitive to persistent terminal complement-med...
Click to show more...

Adsorption, Distribution, Metabolism, Excretion and Toxicity


Not Available from DrugBank


Contact Us:
Please contact us if you have questions or comments about RepurposeDB. You can also contact us if you need help in submitting your drug repositioning investigation to RepurposeDB.


Dudley Laboratory
Department of Genetics and Genomic Sciences
Icahn Institute for Genomics and Multiscale Biology
Icahn School of Medicine at Mount Sinai
One Gustave L. Levy Place, Box 1498
Manhattan, New York City, NY
repurposedb@dudleylab.org